Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Objectives: A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) in uninfected adult volunteers. Methods: Participants were randomized (3:1) to S...

Descripción completa

Detalles Bibliográficos

Autores principales:	Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, Wenjun Zheng, Scott Rasmussen, Danielle Armas, Masaru Oshita, Cynthia Brinson, Steven Folkerth, Lori Faria, Ingeborg Heirman, Neena Sarkar, Bret J. Musser, Shikha Bansal, Meagan P. O'Brien, Kenneth C. Turner, Samit Ganguly, Adnan Mahmood, Ajla Dupljak, Andrea T. Hooper, Jennifer D. Hamilton, Yunji Kim, Bari Kowal, Yuhwen Soo, Gregory P. Geba, Leah Lipsich, Ned Braunstein, George D. Yancopoulos, David M. Weinreich, Gary A. Herman
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2022-09-01
Colección:	International Journal of Infectious Diseases
Materias:	COVID-19 SARS-CoV-2 Monoclonal antibody Casirivimab Imdevimab
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S1201971222003800
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!